ArticleBMC infectious diseases2026
An Antimicrobial susceptibility study to compare the in vitro activity of antimicrobial agents in the Philippines against Enterobacterales and Pseudomonas aeruginosa from different infection sites: results from ATLAS surveillance program (2018-2021).
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis antimicrobial surveillance study reports the in vitro antimicrobial activity and susceptibility data of various antimicrobials against Enterobacterales and Pseudomonas aeruginosa isolates in the Philippines.
methodsIsolates were collected from three clinical sites in the Philippines between 2018 and 2021, as part of the Antimicrobial Testing Leadership and Surveillance (ATLAS) program. A central laboratory (International Health Management Associates, Inc.) performed antimicrobial susceptibility testing using broth microdilution methodology according to Clinical Laboratory Standards Institute (CLSI) guidelines. Minimum inhibitory concentrations (MICs) were interpreted using the CLSI (2023) breakpoints.
resultsA total of 1503 isolates were collected in the ATLAS program from 2018 to 2021. The top three pathogens throughout the study period were Pseudomonas aeruginosa (30.8%), Klebsiella pneumoniae (24.1%), and Escherichia coli (20.8%). Based on the CLSI (2023) breakpoints, isolates of Enterobacterales were highly susceptible to amikacin (98.6%), tigecycline (96.9%) and ceftazidime-avibactam (95.9%), while P. aeruginosa isolates were most susceptible to amikacin (96.5%), ceftazidime-avibactam (94.0%) and ceftolozane-tazobactam (92.7%).
conclusionThe present ATLAS study provides essential insights on the prevalence and susceptibility patterns of Enterobacterales and P. aeruginosa isolates in the Philippines. Ceftazidime-avibactam is a valuable and effective treatment option due to its potent activity against Enterobacterales and P. aeruginosa. Continuous surveillance is important in improving antimicrobial stewardship and antibiotic prescriptions in the country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.